Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Cardiovascular & Haematological Disorders - Drug Targets
  4. Volume 24, Issue 3
  5. Article
Volume 24, Issue 3
  • ISSN: 1871-529X
  • E-ISSN: 2212-4063

Abstract

Background

About 15% of coronary artery interventions are performed on coronary artery bifurcation. Managing these lesions presents a significant therapeutic obstacle in the context of coronary artery issues. Addressing both immediate and lasting side effects of these lesions demands ongoing monitoring and action. The introduction of drug-eluting stents has raised hopes for better outcomes in patients experiencing cardiovascular events.

Methods

In this study, we selected 51 patients (out of 850) who had received ≥1 cobalt-chromium, biodegradable polymer, Biolimus A9-eluting stent (CoCr-BP-BES) Biomatrix Alpha stent. Immediately after stenting, thrombolysis in myocardial infarction (TIMI) flow score in the coronary artery and its bypass branch, plaque shift, and lateral dissection immediately after angioplasty were evaluated.

Results

The mean age for patients was 65 (±10.35) years, where 49.02% of them were male and 45.1% had diabetes. No lateral dissection and death were reported in any of the patients. Also, the TIMI flow grade was 3 for the main branch in all patients. Plaque shifts were compared at different degrees of the TIMI flow coronary artery bypass graft. A statistical study revealed a noteworthy distinction between the groups. There was no discernible change when gender, diabetes, systolic and diastolic blood pressure with plaque changes were all controlled for.

Conclusion

We discovered that the Biomatrix Alpha stents' instant clinical results are admissible. Our findings confirm the clinical utility of the recently developed biolimus-eluting (BES) stent technology, which combines the BA-9 medication, a thin-strut CoCr stent platform, and a biodegradable polymer. This aligns with the existing body of research on the most recent generation of drug-eluting stents (DES).

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X313209240708073302
2024-07-15
2025-01-31

  • From This Site

    /content/journals/chddt/10.2174/011871529X313209240708073302
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ThomT. HaaseN. RosamondW. HowardV.J. RumsfeldJ. ManolioT. ZhengZ.J. FlegalK. O’DonnellC. KittnerS. Lloyd-JonesD. GoffD.C.Jr HongY. AdamsR. FridayG. FurieK. GorelickP. KisselaB. MarlerJ. MeigsJ. RogerV. SidneyS. SorlieP. SteinbergerJ. Wasserthiel-SmollerS. WilsonM. WolfP. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation20061136e85e15116407573
     [Google Scholar]
  2. BodenW.E. Routine invasive versus selective invasive approaches to non–ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era.J. Am. Coll. Cardiol.2003414SS113S12210.1016/S0735‑1097(02)02963‑712644349
     [Google Scholar]
  3. BanningA.P. LassenJ.F. BurzottaF. LefèvreT. DarremontO. Hildick-SmithD. LouvardY. StankovicG. Percutaneous coronary intervention for obstructive bifurcation lesions: The 14th consensus document from the European Bifurcation Club.EuroIntervention2019151909810.4244/EIJ‑D‑19‑0014431105066
     [Google Scholar]
  4. ChieffoA. AranzullaT.C. ColomboA. Drug eluting stents: Focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions.Vasc. Health Risk Manag.20073444145117969375
     [Google Scholar]
  5. MenownI.B.A. MamasM.A. CottonJ.M. Hildick-SmithD. EberliF.R. LeibundgutG. TresukosolD. MacayaC. CoptS. Sadozai SlamaS. StollH.P. First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry.Int. J. Cardiol. Heart Vasc.20202610047210.1016/j.ijcha.2020.10047232140552
     [Google Scholar]
  6. WindeckerS. SerruysP.W. WandelS. BuszmanP. TrznadelS. LinkeA. LenkK. IschingerT. KlaussV. EberliF. CortiR. WijnsW. MoriceM.C. di MarioC. DaviesS. van GeunsR.J. EerdmansP. van EsG.A. MeierB. JüniP. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial.Lancet200837296441163117310.1016/S0140‑6736(08)61244‑118765162
     [Google Scholar]
  7. MaglianoC.A.S. MonteiroA.L. Rebeca de Oliveira RebeloA. PereiraC.C.A. Patients’ preferences for coronary revascularization: A systematic review.Patient Prefer. Adherence201813293510.2147/PPA.S18826830636868
     [Google Scholar]
  8. ChadeA.R. Understanding and managing atherosclerotic renovascular disease: Still a work in progress.F1000 Res.20187186210.12688/f1000research.16369.130631430
     [Google Scholar]
  9. KoutsoumpelisA. ArgyriouC. TasopoulouK.M. GeorgakarakosE.I. GeorgiadisG.S. Novel oral anticoagulants in peripheral artery disease: Current evidence.Curr. Pharm. Des.201924384511451510.2174/138161282566618122615195930585539
     [Google Scholar]
  10. BrownK.N. GuptaN. Percutaneous Transluminal Coronary Arteriography.StatPearls Publishing2020PMID: https://pubmed.ncbi.nlm.nih.gov/30844185/
    [Google Scholar]
  11. SerruysP.W. MoriceM.C. KappeteinA.P. ColomboA. HolmesD.R. MackM.J. StåhleE. FeldmanT.E. van den BrandM. BassE.J. Van DyckN. LeadleyK. DawkinsK.D. MohrF.W. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.N. Engl. J. Med.20093601096197210.1056/NEJMoa080462619228612
     [Google Scholar]
  12. SerruysP.W. SilberS. GargS. van GeunsR.J. RichardtG. BuszmanP.E. KelbækH. van BovenA.J. HofmaS.H. LinkeA. KlaussV. WijnsW. MacayaC. GarotP. DiMarioC. ManoharanG. KornowskiR. IschingerT. BartorelliA. RondenJ. BressersM. GobbensP. NegoitaM. van LeeuwenF. WindeckerS. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.N. Engl. J. Med.2010363213614610.1056/NEJMoa100413020554978
     [Google Scholar]
  13. D'AgastinoP.B. Propensity scores in cardiovascular research.Circulaition.2022115172340310.1161/CIRCULATIONAHA.105.59495217470708
     [Google Scholar]
  14. ViswanathanS. GopinathK. KoshyG. GuptaP.N. VelappanP. Open-labeled randomized controlled trial to evaluate the 1-year clinical outcomes of polymer-free sirolimus-eluting coronary stents as compared with biodegradable polymer-based sirolimus-eluting coronary stents.Indian Heart J.201870Suppl 3 3S323S32810.1016/j.ihj.2018.08.01530595284
     [Google Scholar]
  15. ZotzR.J. DietzU. LindemannS. Genth-ZotzS. Koronare Restenose.Herz2019441353910.1007/s00059‑018‑4777‑030569181
     [Google Scholar]
  16. NgJ. FoinN. AngH.Y. FamJ.M. SenS. NijjerS. PetracoR. Di MarioC. DaviesJ. WongP. Over-expansion capacity and stent design model: An update with contemporary DES platforms.Int. J. Cardiol.201622117117910.1016/j.ijcard.2016.06.09727400317
     [Google Scholar]
  17. MaengM. HolmN.R. ErglisA. KumsarsI. NiemeläM. KervinenK. JensenJ.S. GalløeA. SteigenT.K. WisethR. NarbuteI. GunnesP. MannsverkJ. MeyerdierksO. RotevatnS. NikusK. VikmanS. RavkildeJ. JamesS. AarøeJ. YlitaloA. HelqvistS. SjögrenI. ThayssenP. VirtanenK. PuhakkaM. AiraksinenJ. ChristiansenE.H. LassenJ.F. ThuesenL. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results.J. Am. Coll. Cardiol.2013621303410.1016/j.jacc.2013.04.01523644088
     [Google Scholar]
  18. MenownI MamasMA CottonJM Thin Strut CoCr biodegradable polymer biolimus a9-eluting stents versus thicker strut stainless steel biodegradable polymer biolimus A9-eluting stents: Two-year clinical outcomes.J Interv Cardiol202120216654515
     [Google Scholar]
  19. IantornoM. LipinskiM.J. Garcia-GarciaH.M. ForrestalB.J. RogersT. GajananaD. BuchananK.D. TorgusonR. WeintraubW.S. WaksmanR. Meta-analysis of the impact of strut thickness on outcomes in patients with drug-eluting stents in a coronary artery.Am. J. Cardiol.2018122101652166010.1016/j.amjcard.2018.07.04030292330
     [Google Scholar]
/content/journals/chddt/10.2174/011871529X313209240708073302
Loading
Immediate Destiny of Bifurcation Lesions Treated with Biomatrix Alpha Stents
Cardiovasc Hematol Disord Drug Targets 24, 184 (2024); https://doi.org/10.2174/011871529X313209240708073302
/content/journals/chddt/10.2174/011871529X313209240708073302
/content/journals/chddt/10.2174/011871529X313209240708073302
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): biomatrix Alpha; coronary artery disease; Coronary bifurcate stenosis; drug-eluting stents; immediate clinical outcome; myocardial infarction

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test